Education
About Us
Working with TipRanks
Follow Us
Star Combo Pharma Ltd. (AU:S66)
ASX:S66
S66 Stock Chart & Stats
AU$0.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume100.00K
Average Volume (3M)6.77K
Market Cap
AU$26.33M
Enterprise ValueAU$26.67M
Total Cash (Recent Filing)AU$18.11M
Total Debt (Recent Filing)AU$3.93M
Price to Earnings (P/E)5.0
Beta-0.32
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)0.04
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationThe company converts earnings into cash exceptionally well (OCF/net income 2.04 and FCF growth 178%). Durable cash generation supports reinvestment, dividends, and buffer against downturns, sustaining operations and strategic flexibility over the next 2-6 months.
Conservative Balance SheetVery low leverage (D/E 0.10) and a healthy equity base reduce financial distress risk and preserve funding optionality. Improved ROE (13.78%) indicates shareholder returns are recovering, providing structural resilience and capacity for targeted investments or M&A.
Improved Margins And ProfitabilityHigher gross (22.55%) and net (18.87%) margins reflect better cost management and profitability on the bottom line. If maintained, these margins enhance cash flow generation and fund operations, making the business more robust against revenue cycles over a multi‑month horizon.
Bears Say
Revenue ContractionA decline in sales (-6.34%) signals weakening demand or market share pressure. Top‑line contraction constrains operating leverage, limits sustainable growth runway, and makes future margin improvements harder to sustain without a clear recovery in revenues.
Negative Operating (EBIT) MarginNegative EBIT indicates core operations are not generating operating profit before non‑operating items. This structural operating shortfall can limit reinvestment capacity and suggests earnings are reliant on non‑operational factors, raising medium‑term execution risk.
Potential Earnings Quality ConcernsNet margin gains alongside falling revenue and a negative EBIT imply profits may be boosted by one‑offs or non‑operating items. That raises questions about sustainability of earnings and predictability of cash flows over the next several quarters absent stronger core revenue performance.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$26.33M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 15 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Aug 26, 2025. The company reported AU$0.037 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.037.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.004 which represents an annual dividend yield of 1.54%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0.037 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 18.75%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
14.70%
Trailing 12-Months
Asset Growth
13.16%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Technical Analysis
Zoono Group Limited
―
Nanollose Ltd.
―
Skin Elements Limited
―
Lumos Diagnostics Holdings Ltd.
―
―